Adenoid Cystic Carcinoma Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working, DelveInsight | Ayala Pharmaceuticals, CureVac, Elevar Therapeutics, Actuate Therapeutics, Merck

Adenoid Cystic Carcinoma emerging therapies such as lenvatinib, pembrolizumab, AL101, and others are expected to boost the Adenoid Cystic Carcinoma Market in the upcoming years.

DelveInsight has launched a new report on "Adenoid Cystic Carcinoma - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Adenoid Cystic Carcinoma, historical and forecasted epidemiology as well as the Adenoid Cystic Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Download our sample report @ https://www.delveinsight.com/report-store/adenoid-cystic-carcinoma-acc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Adenoid Cystic Carcinoma Market Report:

According to Calderón Boyle et al. (2020), the incidence rate of Adenoid Cystic Carcinoma (ACC) in the US was 0.35 per 100,000. The limited-duration prevalence was highest among individuals aged 75-79 years and in females, while it was lowest among Native Americans/Alaska Natives. The majority of ACC cases were found in the oral cavity and pharynx.
A multicenter study by Baujat et al. (2020) reported that the average age of ACC patients across Europe was 55 years, with females comprising 59.4% of the cohort. A normal body mass index (BMI) was observed in 86% of cases, and tumors were located in minor salivary glands in 60% of cases. Advanced-stage tumors (T3/T4) accounted for 58% of cases, while 21% had histological grade III tumors. The event-free survival (EFS) rate at five years was 50%, while the overall five-year survival rate was 85%.
In a study conducted by Inagaki et al. (2020) on ACC of salivary gland origin in Japan, the five-year overall survival (OS) and disease-free survival (DFS) rates were 92.5% and 50.0%, respectively. Treatment failure occurred in 46% of cases, with distant metastases observed in 34%.
Several companies are actively working in the Adenoid Cystic Carcinoma market, including Ayala Pharmaceuticals, CureVac, Elevar Therapeutics, Actuate Therapeutics, and Merck & Co., among others.
According to Calderón Boyle et al. (2020), the incidence rate of Adenoid Cystic Carcinoma (ACC) in the U.S. was 0.35 per 100,000. The limited duration prevalence was highest among individuals aged 75-79 years and more common in females, while the lowest prevalence was observed among Native Americans/Alaska Natives. The majority of ACC cases were found in the oral cavity and pharynx.
A multicenter study by Baujat et al. (2020) reported that across Europe, the average age of ACC patients was 55 years, with females comprising 59.4% of the study population. A normal body mass index (BMI) was noted in 86% of cases, and the tumor was located in the minor salivary glands in 60% of patients. Advanced-stage tumors (T3/T4) were present in 58% of cases, while 89% of patients exhibited histological grade III tumors. The event-free survival (EFS) rate was 50%, and the overall 5-year survival rate stood at 85%.
The epidemiology of Adenoid Cystic Carcinoma is categorized in market reports based on total incident cases, gender-specific cases, grade-specific cases, and treatable cases.
Key Adenoid Cystic Carcinoma companies such as Ayala Pharmaceuticals, CureVac, Elevar Therapeutics, Actuate Therapeutics, Merck, and others are evaluating new drugs for Adenoid Cystic Carcinoma to improve the treatment landscape.
Promising Adenoid Cystic Carcinoma pipeline therapies in various stages of development include lenvatinib, pembrolizumab, AL101, and others.
Key benefits of the Adenoid Cystic Carcinoma market report:
Adenoid Cystic Carcinoma market report covers a descriptive overview and comprehensive insight of the Adenoid Cystic Carcinoma Epidemiology and Adenoid Cystic Carcinoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Adenoid Cystic Carcinoma market report provides insights on the current and emerging therapies.
Adenoid Cystic Carcinoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Adenoid Cystic Carcinoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Adenoid Cystic Carcinoma market.

Got queries? Click here to know more about the Adenoid Cystic Carcinoma Market Landscape https://www.delveinsight.com/sample-request/adenoid-cystic-carcinoma-acc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Adenoid Cystic Carcinoma Overview

Adenoid cystic carcinoma (ACC) is a rare type of adenocarcinoma that originates in glandular tissues. While it primarily develops in the salivary glands and other regions of the head and neck, it can also occur in various other parts of the body, including the breast, skin, cervix (in females), and prostate gland (in males). Histologically, ACC tumors exhibit a unique pattern, forming abnormal "nests" or cords of epithelial cells that encircle or invade ducts and glandular structures within the affected organ. These structures often contain a mucous-like substance or fibrous membranes, which are evident under microscopic examination.

The symptoms of ACC vary depending on the tumor's location. In its early stages, salivary gland tumors typically appear as slow-growing, painless masses in the mouth or face. As the disease progresses, it may lead to pain and nerve paralysis. When ACC affects the lacrimal gland, it can cause proptosis and vision changes, while tumors in the tracheobronchial tree may result in respiratory symptoms. If located in the larynx, ACC can lead to voice changes and speech difficulties.

Adenoid Cystic Carcinoma Market Outlook

Surgical resection remains the primary treatment for Adenoid Cystic Carcinoma (ACC), though complications may arise depending on the surgical site. For instance, surgery on the parotid salivary gland carries the risk of facial nerve damage, potentially leading to facial muscle drooping. Clinical trial data suggest that many experts recommend postoperative radiotherapy as an adjuvant treatment to reduce the likelihood of local recurrence. However, in some cases, surgical removal may not be feasible.

When surgery is not an option due to tumor location or disease progression, radiation therapy may be considered. The type of radiation used depends on factors such as cancer type, location, stage, grade, and prior treatments. Additionally, thermal ablation is commonly employed for patients with metastatic disease.

Systemic therapies play a limited role in ACC treatment, as the disease shows minimal response to chemotherapy, which is occasionally used for palliative care. Targeted therapies are still in developmental stages and have yet to become a mainstream treatment option. Although tyrosine kinase inhibitors (TKIs) like lenvatinib and sorafenib have demonstrated promising efficacy, larger studies are needed to establish their effectiveness.

The ACC treatment landscape is expected to evolve in the coming years due to increased awareness and advancements in research and development. Companies such as Merck, Ayala Pharmaceuticals, and others are actively engaged in developing new therapies for ACC.

Read more about the adenoid cystic carcinoma market @ https://www.delveinsight.com/report-store/adenoid-cystic-carcinoma-acc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Adenoid Cystic Carcinoma Emerging Drugs

Merck is currently evaluating the combination of lenvatinib and pembrolizumab in patients with advanced Adenoid Cystic Carcinoma (ACC) and other salivary gland cancers that have recurred or metastasized.

Ayala Pharmaceuticals is developing AL101, an innovative, injectable, and highly selective gamma secretase inhibitor (GSI). The U.S. FDA has granted AL101 both Orphan Drug Designation (ODD) and Fast Track Designation (FTD) for its potential use in treating Adenoid Cystic Carcinoma.

Scope of the Adenoid Cystic Carcinoma Market Report

Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Adenoid Cystic Carcinoma Companies: Ayala Pharmaceuticals, CureVac, Elevar Therapeutics, Actuate Therapeutics, Merck, and others
Key Adenoid Cystic Carcinoma Therapies: lenvatinib, pembrolizumab, AL101, and others
Adenoid Cystic Carcinoma Therapeutic Assessment: Adenoid Cystic Carcinoma current marketed and Adenoid Cystic Carcinoma emerging therapies
Adenoid Cystic Carcinoma Market Dynamics: Adenoid Cystic Carcinoma market drivers and Adenoid Cystic Carcinoma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Adenoid Cystic Carcinoma Unmet Needs, KOL's views, Analyst's views, Adenoid Cystic Carcinoma Market Access and Reimbursement

Request our free adenoid cystic carcinoma market sample report @ https://www.delveinsight.com/report-store/adenoid-cystic-carcinoma-acc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Adenoid Cystic Carcinoma Patient Share (%) Overview at a Glance
5. Adenoid Cystic Carcinoma Market Overview at a Glance
6. Adenoid Cystic Carcinoma Disease Background and Overview
7. Adenoid Cystic Carcinoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Adenoid Cystic Carcinoma
9. Adenoid Cystic Carcinoma Current Treatment and Medical Practices
10. Unmet Needs
11. Adenoid Cystic Carcinoma Emerging Therapies
12. Adenoid Cystic Carcinoma Market Outlook
13. Country-Wise Adenoid Cystic Carcinoma Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Adenoid Cystic Carcinoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Adenoid Cystic Carcinoma Market Outlook 2034 https://www.delveinsight.com/sample-request/adenoid-cystic-carcinoma-acc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Adenoid Cystic Carcinoma Pipeline Insights, DelveInsight

"Adenoid Cystic Carcinoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Adenoid Cystic Carcinoma market. A detailed picture of the Adenoid Cystic Carcinoma pipeline landscape is provided, which includes the disease overview and Adenoid Cystic Carcinoma treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.